Search Results
Dec 22, 2025, 09:00 ET Epilepsy Foundation of America Announces Lampsy Health as Winner of 2025 Startup Accelerator Course
BOWIE, Md., Dec. 22, 2025 /PRNewswire/ -- The Epilepsy Foundation of America (EFA), in partnership with the Danny Did Foundation, announced
More news about: Epilepsy Foundation
Dec 22, 2025, 09:00 ET McCormick & Company to Report 2025 Fourth Quarter Financial Results on January 22, 2026
HUNT VALLEY, Md., Dec. 22, 2025 /PRNewswire/ -- McCormick & Company, Incorporated (NYSE: MKC), a global leader in flavor, is scheduled to conduct a conference call and webcast of its fourth quarter 2025 financial results
More news about: McCormick & Company, Incorporated
Dec 22, 2025, 08:46 ET Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
phosphoribosyl transferase). This protein was first identified as a novel therapeutic target by Aqualung Therapeutics CEO & Founder Joe, GN Garcia MD. eNAMPT is a master regulator of the immune system and contributes to excessive inflammation and scarring (fibrosis) of critical organs. By neutralizing
More news about: Aqualung Therapeutics
Dec 22, 2025, 06:00 ET U.S. Luxury Home Market Shows Mixed Pricing and Divergent Selling Speeds
3Washington-Arlington-Alexandria, DC-VA-MD-WV$1,471,468
More news about: Realtor.com
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
therapy and 74% in patients receiving triplet therapy, when compared with endocrine monotherapy.Lorenzo Gerratana, MD, Associate Professor at the University of Udine and Physician Scientist at IRCCS CRO Aviano (Italy) and first author of the PACE biomarker analysis, said:
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems gibt die Veröffentlichung der Ergebnisse der Biomarker-Analyse der PACE-Studie bekannt, die den klinischen Nutzen der CELLSEARCH® CTC-Zählung für die Behandlung eines bestimmten Subtyps von metastasiertem Brustkrebs bestätigt
Patienten, die eine Dreifachtherapie erhielten, um 74 % im Vergleich zur endokrinen Monotherapie.Lorenzo Gerratana, MD, außerordentlicher Professor an der Universität Udine und Arzt und Wissenschaftler am IRCCS CRO Aviano (Italien) sowie Erstautor der PACE-Biomarker-Analyse,
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
patients receiving doublet therapy and 74% in patients receiving triplet therapy, when compared with endocrine monotherapy.Lorenzo Gerratana, MD, Associate Professor at the University of Udine and Physician Scientist at IRCCS CRO Aviano (Italy) and first author of the PACE biomarker analysis, said:
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems annuncia la pubblicazione dei risultati dello studio PACE, che mostrano il valore clinico della conta delle cellule tumorali circolanti con CELLSEARCH® in uno specifico sottotipo di carcinoma mammario metastatico
e del 74% in quelle trattate con terapia combinata tripla, rispetto alla monoterapia endocrina.Lorenzo Gerratana, MD, Professore Associato presso l'Università di Udine e Medico ricercatore presso l'IRCCS CRO Aviano (Italia), nonché primo autore dell'analisi, ha dichiarato:
More news about: Menarini Silicon Biosystems
Dec 21, 2025, 17:43 ET Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
long-term dedication to the U.S. biopharmaceutical industry and supply chainINCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development
More news about: Samsung Biologics
Dec 20, 2025, 03:00 ET MiniTool Partition Wizard 13.5 veröffentlicht brandneuen Duplikat-Reiniger
bleibt.Erweiterte Scaneinstellungen: Vor dem Scannen können die Benutzer die Scanspeicherorte, Dateitypen, Dateigrößenbereiche und Hash-Vergleichsmethoden (MD5 oder SHA-1) konfigurieren. Große Dateien können mit einem partiellen Hash-Wert gescannt werden, um schnellere Ergebnisse zu erzielen, und wichtige Systemdateien
More news about: MiniTool Software Limited
Dec 19, 2025, 19:31 ET MiniTool Partition Wizard 13.5 リリース - まったく新しい重複データクリーナー
ディスク領域を解放できます。詳細なスキャン設定: スキャンする前に、ユーザーはスキャン場所、ファイルの種類、ファイル サイズの範囲、ハッシュ比較方法 (MD5 または SHA-1) を設定できます。部分ハッシュを使用して大きなファイルをスキャンして結果をより速く得ることができ、重要なシステム ファイルとフォルダーを保護することができます。スマート選択: スキャン結果インターフェースでは、ユーザーは重複ファイルを名前、サイズ、数量、または変更日で並べ替え、フィルタリング、プレビューできます。ワンクリックで重複を安全に削除できます。2.
More news about: MiniTool Software Limited
Dec 19, 2025, 18:00 ET Baker University Provides Notice of a Data Security Event
442-9828; and oag.dc.gov.For Maryland residents, the Maryland Attorney General may be contacted at: 200 St. Paul Place, 16th Floor, Baltimore, MD 21202; 1-410-576-6300 or 1-888-743-0023; and
More news about: Baker University
Dec 19, 2025, 16:41 ET Arizona Urology Specialists Adds Seven Prominent Local Urologists, Opens New Clinics in Phoenix West Valley
Shawn Blick, MD, Lynn Blunt, MD, Paul Bombino, MD, Vincent Chehval, DO, Vi Hua, MD, Torre Rhoades, MD, and Rahul Thaly, MD, have joined AUS, giving the practice the ability to provide urological care throughout a greater
More news about: Arizona Urology Specialists
Dec 19, 2025, 15:00 ET Kirby Medical Center Partners with Switchboard, MD to Automate Patient Communication Workflows
They are committed and proud to provide high-quality, compassionate healthcare services to all people in need.About Switchboard, MDSwitchboard, MD is a physician-led artificial intelligence and data science company with a mission to prioritize the human connection in medicine. Its
More news about: Switchboard, MD
Dec 19, 2025, 14:31 ET Nobu Manchester breaks ground as Robert De Niro visits Manchester with Salboy
bring to Manchester, the city of firsts. This is why it's so fantastic to welcome Nobu to our wonderful city."Simon Ismail, Co-founder and MD of Salboy, added: "Chef Nobu's 30-year influence on our culinary tastes can not be understated and I look forward with huge anticipation for the
More news about: Salboy
Dec 19, 2025, 14:15 ET Nobu Manchester breaks ground as Robert De Niro visits Manchester with Salboy
bring to Manchester, the city of firsts. This is why it's so fantastic to welcome Nobu to our wonderful city."Simon Ismail, Co-founder and MD of Salboy, added: "Chef Nobu's 30-year influence on our culinary tastes can not be understated and I look forward with huge anticipation for the
More news about: Salboy
Dec 19, 2025, 13:35 ET Average Age of First-Time Mothers at AHN Labor and Delivery Units Climbs to 31 Years in 2024, Higher than National Average
said Marcia Klein-Patel, MD, PhD, Chair of AHN Women's Institute. "There are various factors that can contribute to having children later in life, but what I can assure our patients
More news about: Allegheny Health Network
Dec 19, 2025, 12:54 ET Emergency Physicians Share Holiday Safety Tips
"Give yourself and loved ones the gift of safety this holiday season," said ACEP President L. Anthony Cirillo, MD, FACEP. "Simple precautions can help to ensure that this special time of year is spent celebrating with friends and loved ones, rather than visiting the
More news about: American College of Emergency Physicians
Dec 19, 2025, 10:00 ET Vuzix and Collins Aerospace Announce Strategic Collaboration to Scale Augmented Reality Defense Solutions
could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at
More news about: Vuzix Corporation
Dec 19, 2025, 09:07 ET Syncarpha Capital Turns On First Community Solar Project In Maryland, SynerGen Panorama III, LLC
ABINGDON, Md., Dec. 19, 2025 /PRNewswire/ --
More news about: Syncarpha Capital
Dec 19, 2025, 09:03 ET L'Oréal Dermatological Beauty and CeraVe Join Massachusetts General Hospital to Announce First-Ever Endowed Chair in Global Health Dermatology
Dermatological Beauty/CeraVe Endowed Chair in Global Health Dermatology. At a recent celebration of changemakers in skin health held at MGH, Esther E. Freeman, MD, PhD, a highly recognized leader in the rapidly growing field of global health dermatology, was appointed the inaugural Chair of this groundbreaking initiative,
More news about: CeraVe
Dec 19, 2025, 08:30 ET The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute
James Hamrick, MD, MPH, Chairman of the Caris POA. "Their scale, expertise and commitment to research-driven care make them an ideal institution in our shared commitment
More news about: Caris Life Sciences
Dec 19, 2025, 08:00 ET Peer-Reviewed Studies Validate Linus Health AI as an Early Digital Biomarker for Alzheimer's Pathology, Helping People Take Action Earlier to Slow Disease Impact
difficult."Patients need answers long before the 9- to 18-month wait many families face today," said Linus Health Chief Operating Officer John Showalter, MD, MSIS. "AI-based tools can help primary care teams surface the right concerns earlier, direct patients to the right care sooner, and support timely decision-making
More news about: Linus Health
Dec 19, 2025, 07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
profile and strong efficacy including deep and durable responses in 2L+ r/r DLBCL patients treated with ZYNLONTA plus glofitamab," said Mohamed Zaki, MD, PhD, CMO of ADC Therapeutics. "We are well on the way to completing enrollment of approximately 100 patients at the selected dose and plan to
More news about: Equity Insider
Dec 19, 2025, 07:44 ET Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Medicine, and Director of Translational Myeloma Research in the Departments of Lymphoma/Myeloma and Experimental Therapeutics at The University of Texas MD Anderson Cancer Center and the lead investigator for the LINKER-MM4 trial. "These results underscore Lynozyfic's potential as a foundational component
More news about: USA News Group